GPR34 activators are a class of compounds that facilitate the engagement of the GPR34 receptor, a G-protein-coupled receptor (GPCR), with its associated biological pathways. This receptor, encoded by the GPR34 gene, is predominantly expressed in immune and hematopoietic cells and plays a significant role in modulating immune responses and cellular homeostasis. The activators of GPR34 typically work by binding to the extracellular domain of the receptor, thereby triggering a conformational change which activates the intracellular G-proteins. These G-proteins then initiate a cascade of downstream signaling events, leading to the activation of various intracellular pathways such as the phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) pathway. The activation of these pathways by GPR34 activators results in the modulation of cellular functions, including cell survival, proliferation, and migration, which are crucial for the maintenance of normal physiological processes.
The specificity of GPR34 activators is vital for the precision in signaling, ensuring that the activation of the receptor leads to the intended cellular responses without off-target effects. These compounds can include small organic molecules that mimic the action of natural ligands of the receptor, thereby selectively binding and activating GPR34. Through this targeted action, GPR34 activators can influence lipid signaling pathways, as GPR34 has been implicated in the regulation of lysophosphatidylserine levels in biological membranes. The binding of activators to GPR34 can also lead to the activation of downstream effector molecules such as mitogen-activated protein kinases (MAPKs), which further propagate the signal to elicit specific cellular responses. The ability of GPR34 activators to engage these molecular pathways underscores their utility in modulating the receptor's role in cellular communication and signaling networks.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Although primarily acting on its own receptors, sphingosine-1-phosphate may cross-activate GPR34 in certain contexts, enhancing GPR34-mediated signaling through G protein activation. | ||||||
Lysophosphatidic Acid | 325465-93-8 | sc-201053 sc-201053A | 5 mg 25 mg | $98.00 $341.00 | 50 | |
While LPA has its own receptors, it may also interact with GPR34 under specific conditions, enhancing GPR34's GPCR activity and related signaling pathways. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2, though a ligand for its own set of receptors, can also modulate GPR34 activity indirectly by altering the cellular environment and potentially enhancing GPR34 signaling. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin, as a calcium ionophore, can enhance GPR34 activity by increasing intracellular calcium levels, indirectly influencing GPR34 signaling pathways. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular cAMP levels, which can lead to the activation of downstream targets that may enhance GPR34 signaling indirectly through cross-talk with cAMP-dependent pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may then phosphorylate targets involved in GPR34 signaling, thus enhancing GPR34-mediated pathways. | ||||||
Adenosine 5′-Triphosphate, disodium salt | 987-65-5 | sc-202040 sc-202040A | 1 g 5 g | $39.00 $75.00 | 9 | |
ATP, through purinergic signaling, can modulate the cellular environment in a manner that may enhance GPR34 signaling, despite ATP primarily targeting purinergic receptors. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that may affect GPR34 activity indirectly by altering phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels and downstream signaling related to GPR34's context. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that can alter the MAPK signaling pathway, potentially leading to cross-activation or enhancement of GPR34-related pathways. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074, a Raf kinase inhibitor, may influence GPR34 signaling indirectly by modulating the MAPK/ERK pathway, which can intersect with GPR34-related pathways. | ||||||